A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans
Authors:
Open Access
- 21 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 28 (8) , 1830-1836
Abstract
JTT-305/MK-5442 is a calcium-sensing receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. JTT-305/MK-5442 binds to CaSRs, thus preventing receptor activation by Ca2+. In the parathyroid gland, this results in the release of parathyroid hormone (PTH). Sharp spikes in PTH secretion followed by rapid returns to baseline are associated with bone formation, whereas sustained elevation in PTH is associated with bone resorption. We have developed a semimechanistic, nonpopulation model of the time-course relationship between JTT-305/MK-5442 and whole plasma PTH concentrations to describe both the secretion of PTH and the kinetics of its return to baseline levels. We obtained mean concentration data for JTT-305/MK-5442 and whole PTH from a multiple dose study in U.S. postmenopausal women at doses of 5, 10, 15, and 20 mg. We hypothesized that PTH is released from two separate sources: a reservoir that is released rapidly (within minutes) in response to reduction in Ca2+ binding, and a second source released more slowly following hours of reduced Ca2+ binding. We modeled the release rates of these reservoirs as maximum pharmacologic effect (Emax) functions of JTT-305/MK-5442 concentration. Our model describes both the dose-dependence of PTH time of occurrence for maximum drug concentration (Tmax) and maximum concentration of drug (Cmax), and the extent and duration of the observed nonmonotonic return of PTH to baseline levels following JTT-305/MK-5442 administration.Keywords
This publication has 22 references indexed in Scilit:
- Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid HormoneACS Medicinal Chemistry Letters, 2010
- A mathematical model of parathyroid hormone response to acute changes in plasma ionized calcium concentration in humansMathematical Biosciences, 2010
- Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and HumansThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Mechanisms of Anabolic Therapies for OsteoporosisNew England Journal of Medicine, 2007
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- Recent developments in the management of secondary hyperparathyroidismKidney International, 2001
- Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena††Supported in part by Grant No. 24211 from the National Institute of General Medical Science, National Institutes of Health.Journal of Pharmaceutical Sciences, 1998
- Individual parathyroid cells exhibit cyclic secretion of parathyroid hormone and chromogranin-A (as measured by a novel sequential hemolytic plaque assay)Endocrinology, 1992
- Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormoneJournal of Bone and Mineral Research, 1992